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Background: The brain endothelium is a key component of the blood brain barrier which is compromised
following ischemia, allowing infiltration of damaging immune cells and other inflammatory molecules into the
brain. Intravenous immunoglobulin (IVIg) is known to reduce infarct size in a mouse model of experimental stroke.
Findings: Flow cytometry analysis showed that the protective effect of IVIg in ischemia and reperfusion injury
in vivo is associated with reduced leukocyte infiltration, suggesting an involvement of the endothelium. In an
in vitro model of ischemia, permeability analysis of the mouse brain endothelial cell line bEnd.3 revealed that IVIg
prevented the loss of permeability caused by oxygen and glucose deprivation (OGD). In addition, western blot
analysis of these brain endothelial cells showed that IVIg prevented the down-regulation of tight junction proteins
claudin 5 and occludin and the decline in anti-apoptotic proteins Bcl-2 and Bcl-XL caused by OGD.
Conclusion: IVIg protects endothelial cells from ischemic insult. These studies support the use of IVIg as a
pharmacological intervention for stroke therapy.
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Intravenous immunoglobulin (IVIg) is a purified con-
centrated human immunoglobulin solution composed
primarily of IgG, obtained by fractionating blood plasma
from a pool of healthy donors. Due to its immuno-
modulatory and anti-inflammatory effects, IVIg is used
as a therapeutic modality for many immune disorders, in-
cluding those that affect the nervous system [1]. We have
shown that IVIg treatment reduces brain infarct volume
and mortality in a mouse model of stroke [2,3]. We have
also observed in in vivo and in vitro mouse models of
stroke that IVIg promotes neuronal survival by inhibiting
the activation of inflammasomes and apoptotic signaling
and by increasing the levels of the anti-apoptotic protein
B-cell lymphoma 2 (Bcl-2) [3,4].* Correspondence: s.manzanero@uq.edu.au
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article, unless otherwise stated.In response to the local and systemic inflammation
that occurs following stroke, the cerebral vasculature
is subjected to endothelial cell activation, leukocyte-
endothelial cell adhesion, blood brain barrier (BBB)
dysfunction, activation of glial cells and an enhanced
generation of inflammatory mediators [5]. Clinical inter-
vention to attenuate and/or delay BBB dysfunction may
improve neurological outcome and facilitate patient
recovery. Animal studies have shown that administration
of IVIg impairs leukocyte adhesion to endothelial cells,
attenuates complement-mediated damage, modulates
cytokine production by various cell types and inhibits
apoptosis [2,6-8]. However, it is not known whether
IVIg protects from cerebrovascular dysfunction following
ischemic stroke. Endothelial permeability, the ability
of the endothelial cell monolayer to restrict the trans-
fer of solutes from the blood to the brain parenchyma,
is essential for cerebrovascular function. Endothelial
permeability comprises paracellular and transcellular
mechanisms, and tight junctions are a key component ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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injury. Therefore, measuring tight junction proteins
has been shown as a valid indicator of the paracellular
pathway of endothelial permeability and its damage in
ischemic injury [9]. The findings of this study reveal a
beneficial effect by IVIg on ischemia-induced leukocyte
recruitment as well as on endothelial permeability (medi-
ated by tight-junction proteins claudin 5 and occludin),
as well as an anti-apoptotic effect on endothelial cells
mediated by Bcl-2 and Bcl-XL.
Materials and methods
Focal cerebral ischemia/reperfusion (I/R) stroke model
Three-month-old C57BL/6 J male mice were sourced
from the Animal Resources Centre, Western Australia, and
subjected to transient middle cerebral artery occlusion for
1 h followed by reperfusion, as described previously [2].
Neurological deficit, the functional abnormalities observed
in mice as a result of brain damage, were scored on a
five-point scale: 0, no deficit; 1, failure to extend right
paw; 2, circling to the right; 3, falling to the right; and
4, unable to walk spontaneously. Only animals that
showed a neurological deficit score of 1 to 3, consistent
with moderate stroke damage [2,5], were used. Of 24
mice, 4 mice were excluded due to lack of neurological
deficit (inclusion 83.4%). 8 mice were administered 2 g/kg
of IVIg (250 μl; Kiovig, Baxter) by infusion into the
femoral vein 3 h after reperfusion by an independent
investigator and the remaining 12 mice were administered
the vehicle phosphate-buffered saline (PBS). For each
experiment, each group of mice was placed in a separate
box after IVIg or vehicle injection and boxes were coded
to ensure blind allocation. These experiments were
approved by the Animal Care and Use Committee of
The University of Queensland (Australia).
Flow cytometry
Flow cytometric analysis of immune cells was performed
as previously described [5]. Animals were euthanized and
perfused with PBS. Ipsilateral hemispheres were dissected,
digested for 30 min at 37°C (1 mg/mL collagenase,
0.1 mg/mL DNAse I in Dulbecco's Modified Eagle's
Medium, DMEM), and passed through a cell strainer.
Cells were incubated with standard erythrocyte lysis
buffer on ice and separated from myelin and debris by
Percoll gradient (GE Healthcare) centrifugation. After
staining of surface markers for CD45 (30-F11, 1:100) and
CD11b (M170, 1:300), cells were fixed using fixation
buffer (all eBioscience). Data were acquired with a LSR II
FACS system and analyzed with FACSDiva (both BD Bio-
sciences). Doublets were excluded with FSC-A and FSC-H
linearity. 4 independent experiments were carried out on
different days, each with 2 to 3 pooled animals per sample,
to obtain adequate statistical power [5].Oxygen and glucose deprivation (OGD)
The murine brain endothelial cell line bEnd.3 (ATCC
CRL-2299) was grown to confluence in DMEM supple-
mented with 10% fetal bovine serum, 1% penicillin/
streptomycin and 1% L-glutamine (all Life Technologies).
OGD was induced by exposing the cells to Locke’s buffer
[3] for 10 min before incubation in an oxygen-free
chamber with 95% N2, 5% CO2 for 0.5-3 h. IVIg was
added at the reported concentrations and proline (Sigma
Aldrich), an aminoacid with no known affinity for any cell
receptors, was used at a concentration of 5 mg/mL as
vehicle control for all experiments.Permeability assay
In order to assess the effect of IVIg on cell permeability
during OGD, endothelial bEnd.3 cells were grown on
0.4 μm pore membrane cell culture inserts (Nunc) on 24
well plates. Cells were cultured on the upper side of the
insert and allowed to grow to confluence. 5 mg/mL
FITC-dextran (Sigma Aldrich) was added to the upper
chamber containing IVIg and Locke’s buffer before
exposure to OGD. After 3 h, 100 μl of media from the
lower chamber was collected and the amount of FITC-
dextran was measured using a fluorescence plate reader
Varioskan (Thermo Scientific) at absorbance and emission
wavelengths of 492 nm and 520 nm respectively.Lactate dehydrogenase assay
The bEnd.3 cells were cultured in 24 well plates until
confluent before OGD treatment in the presence or
absence of IVIg for 0.5, 1, 2 or 3 h. The LDH assay was
performed according to the manufacturer’s instructions
(Roche), except that samples were incubated with the
reaction solution for 1 h. The reaction was stopped by
adding 1 N HCl, and absorbance was measured on the
different sample wells. Each sample measurement was
carried out in triplicate.Immunoblotting
Protein samples were run for sodium dodecyl sulfate–
polyacrylamide (10%) gel electrophoresis and then electro-
blotted onto a nitrocellulose membrane. The membrane
was blocked for 1 h and incubated overnight at 4°C with
antibodies selective for occludin (Life Technologies),
claudin 5 (Life Technologies), JAM-A (Santa Cruz), ZO-1
(Abcam), AIF (Cell Signaling), Bcl-2 (Cell Signaling),
Bcl-XL (Cell Signaling) and β-actin (Sigma Aldrich).
After washing, the membrane was incubated with secon-
dary antibodies for 1 h, washed again and incubated with
substrate for enhanced chemiluminescence (Pierce). After
visualization on X-ray films (Fujifilm), protein levels were
quantified by densitometry using Image J software.
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bEnd.3 cells were cultured on microscope coverslips,
exposed to OGD and treated with IVIg or vehicle, and
fixed in 4% paraformaldehyde. Incubation for 1 h with
claudin 5 (Cell Signaling) antibody was followed by
incubation with Alexa fluor 488 conjugated secondary
antibody (Life Technologies). Nuclei were stained with
DAPI and mounted with VectaShield (Vector). Images
were acquired using a fluorescence microscope (Olympus).
Data analysis
Statistical power was calculated using an expected 50%
reduction in inflammatory infiltrate and permeability,
and a 50% increase in protein levels between vehicle
and IVIg treated samples, based on previous results
from our laboratory [2-4]. All the results are reported as
means ± SEM. Overall data significance was examined by
one-way analysis of variance (ANOVA). The differences
between groups were considered significant at p < 0.05
using Bonferroni correction for multiple comparisons.
Results
IVIg treatment reduces leukocyte infiltration and protects
against OGD-induced brain endothelial damage
Ischemic stroke promotes leukocyte recruitment to the
injured tissue [5]. The first aim was to determine whether
the IVIg dose previously shown as optimal to reduce
infarct size 72 h after ischemia and reperfusion in this
mouse model [2] was able to decrease leukocyte infiltra-
tion to the ischemic hemisphere at 24 h. The chosen time
point of IVIg infusion was 3 h post-reperfusion, as this
was the latest time point previously shown to reduce
infarct size [2], and late intervention supports clinical
application. Our data showed that presence of CD45high
immune cells in the ipsilateral hemisphere 24 h post-
ischemia was attenuated in IVIg-treated mice compared
to vehicle-treated controls (Figure 1A and B). Since
tight regulation of endothelial permeability is pivotal to
BBB integrity, we next assessed the effect of IVIg on
permeability using the mouse brain endothelial cell line
bEnd.3, measured as the ability for FITC-dextran to
cross the cell monolayer 3 h after oxygen and glucose
deprivation (OGD). IVIg-treated cells exhibited reduced
permeability compared with control cells (Figure 1C). In
order to investigate whether this was a consequence of
tight junction protein modulation, we assessed expression
levels of claudin 5, occludin, junctional adhesion molecule
1 (JAM-1) and zona occludens-1 (ZO-1). Immunoblot
analyses showed that expression of each of these tight
junction proteins was reduced after 3 h OGD (Figure 1D-
H). However, the decline in claudin 5 and occludin levels
was completely rescued in the presence of IVIg (Figure 1E
and F). Immunocytochemistry confirmed the disappear-
ance of claudin 5 from the membranes of OGD-treatedendothelial cells and the conservation of claudin 5 integ-
rity in the presence of IVIg (Figure 1I). Overall these
results point to a beneficial effect of IVIg on the mainten-
ance of tight-junction proteins claudin 5 and occludin
during ischemic stress, which would strengthen the BBB
and contribute to a decreased leukocyte infiltration after
ischemia.
IVIg protects brain endothelial cells against OGD-induced
cell death by up-regulating anti-apoptotic proteins
Next, we investigated the effect of IVIg on the survival
of brain endothelial cells during OGD. bEnd.3 cells
treated with IVIg showed consistently low levels of
LDH release throughout an OGD time course up to
3 h, indicative of a protective effect of IVIg against
OGD-induced cell death (Figure 2A). In order to better
understand the underlying mechanisms, analyses of
apoptosis inducing factor (AIF), Bcl-2, and Bcl-XL were
carried out by immunoblotting. IVIg treatment tended
to reduce the increase in AIF observed following 2–3 h
OGD, however this effect did not reach statistical signifi-
cance (Figure 2B and 2C). However, IVIg significantly
prevented the OGD-induced decreases of both Bcl-2
and Bcl-XL observed in untreated cultures (Figure 2D-F).
These data support an action of IVIg to protect cere-
bral endothelial cells from undergoing ischemia-induced
apoptosis.
Discussion
We [2,3] and others [10,11] have previously demonstrated
that IVIg treatment reduces brain infarct volume and
mortality in experimental rodent models of stroke. This
study reveals a protective effect of IVIg against endothelial
dysfunction following ischemic stroke, in association with
reduced leukocyte infiltration in vivo. The data indicate
that IVIg provides a two-way protective mechanism
for cerebral endothelial cells, firstly by blocking the
increase in BBB permeability involving downregulation
of tight-junction proteins claudin 5 and occludin, and
secondly by preventing ischemia-induced endothelial
cell death involving a reduction in anti-apoptotic proteins,
Bcl-2 and Bcl-XL.
This study shows for the first time that infusion of a
high dose of IVIg (2 g/kg body weight) 3 h after reperfu-
sion reduces leukocyte infiltration into the brain. Ischemic
stroke causes endothelial cell dysfunction with the break-
down of tight junction proteins and compromised BBB
function, leading to increased protein extravasation, inter-
stitial edema and the adhesion and transmigration of
leukocytes [12]. We have previously demonstrated the
injurious role of infiltrating immune cells in the patho-
genesis of post-ischemic brain injury in mice [5], and
the beneficial effects of IVIg treatment on the levels of
inflammatory endothelial and leukocyte adhesion molecules
Figure 1 IVIg prevents post-ischemic leukocyte infiltration and maintains blood brain barrier integrity. (A) Administration of IVIg (2 g/kg)
decreased leukocyte infiltration following 1 h and 23 h respectively of cerebral ischemia and reperfusion (I/R). **p < 0.01 compared to I/R mice, n = 8-12.
(B) Representative flow cytometry plots showing the two studied populations of CD45+ cells, infiltrating leukocytes (CD45 high) and microglia (CD45
intermediate). (C) Treatment with high concentration of IVIg (5 mg/mL) reduced permeability of bEnd.3 cell monolayers subjected to oxygen and
glucose deprivation (OGD). *p < 0.05 compared to OGD 3 h. (D, E and F) IVIg rescues the decrease in claudin 5 and occludin levels that occurs after
3 h OGD in untreated or vehicle controls. **p < 0.01. (G and H) A similar trend was seen in the expression levels of JAM-1 and ZO-1, however statistical
significance was not reached. (I) Immunofluorescence staining showed the restoration of claudin 5 expression in IVIg-treated bEnd.3 cells subjected to
3 h OGD. Scale bar: 20 μm.
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Figure 2 IVIg promotes endothelial cell survival in OGD. (A) IVIg treatment reduced LDH release from bEnd.3 cells subjected to 1–3 h OGD.
*** p < 0.001 as indicated by bars. (B and C) IVIg moderated the increase in AIF levels in bEnd.3 cells, however statistical significance was not reached.
(D, E and F) IVIg prevented the decrease in Bcl-2 and Bcl-XL levels measured in bEnd.3 lysates following 3 h OGD. *** p < 0.001, * p < 0.05 as indicated
by bars.
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ischemic stroke [2].
Ischemic stroke compromises BBB integrity, which is
mediated by cytoskeleton rearrangement, and redistribu-
tion and disappearance of tight junction proteins such
as claudin 5 and occludin in brain endothelial cells,
resulting in increased BBB permeability [13]. Our results
show that endothelial permeability, which is vulnerable
to OGD, remains unaffected by OGD in the presence of
IVIg. In accordance with this finding, the loss of key
tight-junction proteins claudin 5 and occludin in OGD
does not occur when IVIg is present. IVIg could, therefore,
prevent the loss of tight junction integrity in the brain
and consequently protect the BBB whose breakdown
contributes to a large part of stroke-induced injury. A
recent study investigating the effect of IVIg on BBB
integrity in a sepsis model suggested that immunoglobulin
G, A, or M improved the integrity of the BBB and inhib-
ited symptoms of sickness in rats [14]. We previously
reported that IVIg crosses the BBB and exerts protectiveeffects in a mouse model of stroke [2,3]. There are two
ways in which IVIg may be able to reduce BBB permeabi-
lity and at the same time be able to cross the BBB – while
IVIg may cross the intact BBB, as reported recently in
mouse [15], it is also possible that IVIg crosses the da-
maged BBB and then exerts its permeability modulation
once in the brain parenchyma.
This study highlights a previously unrecognised bene-
ficial action of IVIg on cerebral endothelial cells exposed
to ischemia, in that cell death is inhibited and levels of
Bcl-2 and Bcl-XL are preserved. Bcl-2 and Bcl-XL play
pivotal roles in determining cell survival or death under
conditions of stress, and have both been shown to pre-
vent endothelial cell death [16]. Ischemic conditions, or
exposure to Aβ, promote a decline in Bcl-2 levels and
subsequently increase apoptosis in mouse primary cortical
neurons, but the presence of IVIg maintains high Bcl-2
levels and low cell death rates [3]. In physiological terms,
IVIg could potentially be responsible for the survival of a
number of vessels in the penumbra that would otherwise
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to the extension of the infarct. Taken together, these data
indicate that IVIg has significant protective characteristics
for inhibiting endothelial, as well as neuronal cell death
following ischemic stroke. In addition to the known
neuroprotective role of IVIg, we have demonstrated that
IVIg acts through multiple mechanisms to protect brain
tissue after stroke. Specifically, our present findings pro-
vide evidence that IVIg inhibits endothelial dysfunction
and death and reduces leukocyte infiltration following
ischemic stroke.
The current view in stroke treatment supports the
notion of stroke therapies that affect multiple injury
mechanisms simultaneously. IVIg, with its effects on
neurons, inflammatory cells and endothelium fits this
definition perfectly and as such promises to be a relevant
candidate for translational research to the clinic.
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